Innovation,
the Archeon's DNA

Innovating healthcare with Archeon Medical:
redefining patient ventilation

At Archeon Medical, innovation is not just a part of our DNA; it defines who we are. Since 2018, we have been at the forefront of revolutionizing emergency medicine with a groundbreaking approach to manual ventilation monitoring.

 

In the landscape of pre-hospital cardiopulmonary resuscitation (CPR), the emphasis has traditionally been placed on cardiac massage techniques, inadvertently overlooking the critical aspect of ventilation. This oversight underscores the pressing need for a paradigm shift towards a comprehensive approach that integrates effective ventilation strategies alongside cardiac support.

While the practice of manual ventilation had remained unchanged for decades, Archeon decided to address this issue to transform the practice and make it accessible to a wider audience through the EOlife technology. The recent birth of ventilation feedback devices embodies a revolution within the ventilation monitoring landscape. Our flagship device, EOlife, represents this paradigm shift in patient ventilation. It provides efficient and personalized ventilation to each patient, measuring the delivered oxygen tidal volume with unmatched precision and simplicity. This innovation has transformed the landscape of cardiopulmonary resuscitation (CPR), offering a new standard of care in airway management.

 

Archeon is leading the charge in harnessing artificial intelligence to optimize patient ventilation in life-threatening situations. Archeon’s dedicated team of engineers is continuously developing cutting-edge technologies to assist healthcare teams in providing optimal ventilation support.

MADE IN FRANCE Excellence

Archeon’s commitment to technological and industrial sovereignty is evident in the “Made in France” ethos. Designed and manufactured in France, EOlife is now marketed in over 15 countries across Europe, the Middle East, Asia-Pacific, and North America. Archeon’s innovations have been recognized globally for their portability, ergonomics, and simplicity, earning multiple Innovation Prizes.

A visionary response to public health challenges

In the face of recent epidemics like COVID-19, H1N1, and Ebola, respiratory issues have emerged as a critical health concern. Archeon’s technology addresses this urgent need for effective ventilation, particularly in emergencies where timely intervention can mean the difference between life and death.

 

When examining CPR statistics, the survival rate stands at a mere 5%. However, proficient ventilation techniques have the potential to triple survival chances (1). EOlife enhances manual ventilation quality by over 70%, simultaneously reducing the risk of hyperventilation by a factor of 10 (2). Investing in high-performance ventilation not only increases survival probabilities but also mitigates long-term complications and shortens intensive care stays (3), leading to significant cost savings for healthcare systems. (4).

 

Shifting the focus to ventilation within the CPR context reframes the objective: it’s not just about saving lives but also about enabling survivors to regain normalcy. Improving ventilation outcomes not only increases survival rates but also diminishes long-term sequelae: pulmonary (5) and neurological (6) outcomes.

Our mission is to revolutionize healthcare

Archeon’s mission is clear: to make cutting-edge technologies accessible to healthcare professionals worldwide, thereby improving patient care. Archeon is committed to setting a new standard of care in high-performance ventilation and continually innovating to ensure protective ventilation for all patients. Our latest generation of monitors is poised to become the new norm in healthcare by 2026, with the ambitious goal of saving one million lives annually.

 

Archeon Medical is not just a company; it’s a beacon of innovation in healthcare. With our revolutionary technology, commitment to excellence, and visionary approach to public health challenges, we’re reshaping the future of airway management and CPR.

References
  1. Idris, A. H., Aramendi Ecenarro, E., Leroux, B., Jaureguibeitia, X., Yang, B. Y., Shaver, S., … Wang, H. E. (2023). Bag-Valve-Mask Ventilation and Survival From Out-of-Hospital Cardiac Arrest: A Multicenter Study. Circulation, 148. DOI: 10.1161/CIRCULATIONAHA.123.065561.
  2. Khoury A, De Luca A, Sall FS, Pazart L, Capellier G. Ventilation feedback device for manual ventilation in simulated respiratory arrest a crossover manikin study Scand J Trauma Resusc Emerg Med. 2019 Oct 22;27(1):93
  3. Mongardon N, Perbet S, et al. Infectious complications in out-of-hospital cardiac arrest patients in the therapeutic hypothermia era. Crit Care Med. 2011;39(6):1359-1364.
  4. Joseph F Dasta 1, Trent P McLaughlin, Samir H Mody, Catherine Tak Piech. Daily cost of an intensive care unit day: the contribution of mechanical ventilationa. Crit Care Med. 2005 Jun;33(6):1266-71.
  5. Mongardon N, Perbet S, et al. Infectious complications in out-of-hospital cardiac arrest patients in the therapeutic hypothermia era. Crit Care Med. 2011;39(6):1359-1364.
  6. Idris, A. H., Aramendi Ecenarro, E., Leroux, B., Jaureguibeitia, X., Yang, B. Y., Shaver, S., … Wang, H. E. (2023). Bag-Valve-Mask Ventilation and Survival From Out-of-Hospital Cardiac Arrest: A Multicenter Study. Circulation, 148. DOI: 10.1161/CIRCULATIONAHA.123.065561.
Scroll to Top